Fenwick Represents Inipharm in $35 Million Series A Financing

Fenwick represented Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, in its $35 million Series A financing.

Inipharm plans to use the Series A funding to support the advancement of its lead program through IND filing and into clinical trials. More information can be obtained from Inipharm’s announcement.

The Fenwick transaction team was led by corporate partner Matthew Rossiter and associates Christine Chen, Shweta Kumar and Monica Zwolinski.